Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favourable/Intermediate Risk: Multicentre Randomised Trial CROSS-J-RCC

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2020.01.001
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Sunitinib Induced Cytopenia in Metastatic RCC

Clinical Medical Reviews and Case Reports
2018English

Rare Case of Tubulocystic RCC in Association With Papillary RCC

BMJ Case Reports
Medicine
2019English

Randomized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib Versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

RCC With Cavo-Atrial Extensions

Japanese Journal of Urology
Urology
2005English

Laparoscopic Cholecystectomy Versus Percutaneous Catheter Drainage for Acute Cholecystitis in High Risk Patients (CHOCOLATE): Multicentre Randomised Clinical Trial

British Medical Journal
Medicine
2018English

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to the Bone Using Stereotactic Body Radiation Therapy: Is RCC Truly Radioresistant?

Practical Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2015English

Two-Drug Cocktail Active Against RCC

Cancer Discovery
Oncology
2018English

PCN10 Targeted Therapy (TT) for First Line Treatment of Advanced Renal Cell Carcinoma (RCC): An Indirect Comparison Meta-Analysis (ICMA)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

The Lancet
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy